Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.

Trial Details

NCT ID
NCT06613100
Phase
PHASE1
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Xaluritamig
  • GnRH Antagonist
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Myrtle Beach, South Carolina, United States|33.68906,-78.88669

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all the following criteria apply:
  • Participants planned to undergo radical prostatectomy.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or…
  • Gleason score of 4+3 or higher AND initial PSA (iPSA) \>10 OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →